Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods
- 323 Downloads
In the present study, we undertook an equivalence analysis on the effectiveness of the main anti-reabsorptive agents indicated for women with osteoporosis.
Our methodology was a combination of meta-analysis (both pair-wise meta-analysis and network meta-analysis) and equivalence testing. The end-point was the incidence on new vertebral fractures. The anti-reabsorptive agents examined included alendronate, zoledronate, ibandronate, risedronate, and denosumab.
Our analysis involved nine randomized trials. Ten head-to-head indirect comparisons were examined through network meta-analysis and the respective values of RR were estimated. The 95 % confidence intervals for RR remained within the interval of a relative ±40 % variation for all comparisons that involved alendronate, risedronate, ibandronate, and denosumab. In contrast, the comparisons involving zoledronate satisfied a post hoc margin up to ±67 %.
Our results confirm that most of these anti-reabsorptive drugs (namely, alendronate, risedronate, ibandronate, and denosumab) are equivalent according to reasonable equivalence margins.
KeywordsMeta-analysis Equivalence Osteoporosis Ibandronate Alendronate Risedronate Denosumab
Conflict of interest
- 2.Messori A, Fadda V, Maratea D, Trippoli S (2014) The Italian way to evidence-based demonstration of equivalence as a prerequisite for conducting procurement tendering within the NHS (Rapid Response), thebmj. http://www.bmj.com/content/347/bmj.f4951/rr/759376. Accessed 1 July 2014
- 7.Messori A (2014) Comment, PubMed Commons. Available at http://www.ncbi.nlm.nih.gov/pubmed/23543450/#comments. Accessed 5 Apr 2014